The women's-health angle on GLP-1.

The midlife metabolic shift is real. How GLP-1 medicines fit alongside the hormonal changes of the menopause transition — and what to weigh.

4 cited sources

Appetite, the menstrual cycle, birth control absorption and pregnancy — the women's-specific questions worth raising before you start a GLP-1.

4 cited sources

A women's-health checklist for picking a GLP-1 provider: hormonal suitability, labs, clinical oversight and price — not just the cheapest vial.

4 cited sources

What the compounded-vs-brand choice really means for women: what the evidence covers, what compounding is, and how to decide with a clinician.

5 cited sources

How semaglutide and tirzepatide compare for women — mechanism, weight-loss results and why insulin resistance shapes the choice.

4 cited sources

The metabolic mechanism behind stubborn weight in women — how insulin resistance works and where GLP-1 medicines act on it.

4 cited sources

A measured women's-lens look at GLP-1 cost and starting safely: 503A vs 503B pharmacies, LegitScript, FDA compounding and what to verify.

3 cited sources

A women's-health guide to labs and monitoring on GLP-1: which markers matter, why oversight counts, and what to ask a provider to track.

4 cited sources

Does a GLP-1 affect your birth control? Why tirzepatide can lower the pill's reliability, semaglutide differs, and the fertility catch behind Ozempic babies.

11 cited sources

Shedding on a GLP-1 is usually not one thing. How to tell medication-linked hair loss from perimenopausal thinning, PCOS, and low ferritin.

6 cited sources

Some lean mass goes with any weight loss. Why midlife stacks that on a decline already underway — and what the evidence in women actually supports.

7 cited sources

A GLP-1 trial in adults with fracture risk found lower hip and spine bone density at 52 weeks. What that means layered onto menopausal bone loss.

6 cited sources

The FDA label treats the semaglutide tablet and injection differently for breastfeeding. What the new human milk data shows, and what it doesn't yet.

6 cited sources

GLP-1s raise gallbladder disease risk most in weight-loss trials specifically. Why estrogen already puts women 2-3x higher than men, and the symptoms to know.

6 cited sources

The label warning about thyroid tumors is not the same question as Hashimoto's or hypothyroidism, which affect women far more. What actually matters for each.

7 cited sources

Obesity is a real, established risk factor for postmenopausal breast cancer. What new survivor data on GLP-1 use shows — and what questions remain open.

7 cited sources

GLP-1s show real promise for binge eating disorder — and the same appetite suppression can reinforce restriction in a history of anorexia. What to ask.

5 cited sources

IIH is a condition that affects almost exclusively women — and a randomized trial found a GLP-1 lowered intracranial pressure directly. What the evidence shows.

8 cited sources

Rheumatoid arthritis and lupus both skew heavily female. What early evidence shows about GLP-1 medication and disease activity — and what remains unproven.

8 cited sources

Weight loss before IVF is often recommended, but a GLP-1 raises real timing questions around egg retrieval and embryo transfer. What the evidence shows.

7 cited sources

Semaglutide's landmark cardiovascular trial enrolled a population that was 72.5% male. What that means for how much the results actually tell women.

6 cited sources

The Edit's semaglutide and tirzepatide ladder is the only one of seven we could not break on arithmetic. What we verified in August 2026, and what we could not.

3 cited sources

Pepti renders $99 semaglutide flat at every dose — while its own production data carries a per-dose ladder up to $449. We could not break the tie. Here is why.

3 cited sources

Trellis publishes the best-formed GLP-1 price table of seven providers we screened — and four other programs with no ladder at all. Verified August 2026.

5 cited sources

Auren Rx prints an explicit no-commitment rung on every product — then never says which states it serves. What we verified in August 2026, and the two traps.

2 cited sources

He & She MD prices its GLP-1 line down to the dollar and its estradiol and progesterone line not at all. It does name its pharmacy in full.

2 cited sources

HumeCare+ ships a body analyzer with the medication and reads fat and lean mass weekly. It also publishes no price until you have finished the medical intake.

2 cited sources

Vyvron bills every four weeks while printing '/mo', and has no monthly tirzepatide plan at all. The arithmetic, the disclosures it gets right, August 2026.

3 cited sources

Every Rehydra+ GLP-1 membership is a six-month non-cancelable contract. The advertised $119/mo is really $714 committed. What we verified in August 2026.

2 cited sources

Lighter You names four pharmacies with street addresses and publishes no price you can verify. Its $99 headline buys nothing. What we found in August 2026.

3 cited sources